Read the latest positive news, breakthroughs, and inspiring stories about eli lilly, curated daily by BrightWire.
Eli Lilly's experimental drug retatrutide outperformed the widely-used Ozempic in lowering blood sugar and reducing weight in a major diabetes study. The breakthrough offers new hope for millions managing type 2 diabetes.
The FDA just approved a new first-line treatment for chronic lymphocytic leukemia, giving patients a breakthrough option right from diagnosis. Eli Lilly's Jaypirca can now be prescribed earlier in the cancer journey, potentially improving outcomes for thousands. ---
A major pharmaceutical company is turning decades of failed experiments into AI training gold, potentially cutting drug development time from 15 years to days. The secret weapon? Learning from what didn't work.
Eli Lilly will now let more patients access its unapproved obesity drug retatrutide through a special program. The decision came after the company initially granted access to just one patient.
Eli Lilly is preparing to seek FDA approval for retatrutide, a groundbreaking obesity drug that helped people lose up to 30% of their body weight in clinical trials. The medicine could offer hope to millions struggling with obesity when it reaches the market in 2027.
Eli Lilly has granted one person extraordinary access to its next-generation obesity treatment through an FDA compassionate use program. The decision marks a rare exception that could offer hope to patients waiting for breakthrough treatments.
A breakthrough obesity treatment helped patients lose nearly 30% of their body weight—results previously only achievable through surgery. The experimental drug could transform how millions manage obesity while Medicare makes these treatments more affordable.
A revolutionary gene-editing treatment from Eli Lilly can slash bad cholesterol by up to 62% with just one dose, and the effects last for years. The breakthrough could transform how we prevent heart disease, America's leading killer.
A one-time gene-editing treatment lowered dangerous cholesterol levels by 62% in early human trials, offering hope for millions who struggle with heart disease prevention. The therapy produced no serious side effects, marking a major safety milestone.
A one-time gene-editing treatment slashed bad cholesterol by 62% in early human trials, offering hope for millions who struggle with heart disease prevention. Eli Lilly's breakthrough therapy showed no serious side effects in the study.
Eli Lilly's experimental obesity medication helped patients lose an average of 28% of their body weight in a major trial, matching results typically seen only with bariatric surgery. The breakthrough treatment offers new hope for millions struggling with obesity, though researchers are working to reduce side effects.
The FDA just approved a new obesity pill that's easier to take than any competitor, and it hit pharmacy shelves in record-breaking time. Patients now have more options than ever to manage their weight without needles.